arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ADMA BIOLOGICS, INC.

ADMA
$9.83 ▲ +0.32 (+3.42%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
73 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Bullish
auto_awesome

Analytical Summary

ADMA BIOLOGICS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $2.2B
Dividend Yield
Revenue Growth 2.0%
Op. Margin 42.2%
ROIC 6.5%
FCF / Share $0.12
Trailing P/E 57.8x
Price / Book 5.4x
FCF Yield 1.2%
Debt / Equity 0.48
info Valuation on last close. End-of-day price, Sep 22, 2026.

73-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$124.39M
↑ +2.0%
Net Income Profit after all expenses
$45.33M
↑ +68.5%
Operating Margin Operating profit as % of sales
42.2%
↓ -17.2% 92th
FCF / Share Free cash flow per share
$0.12
↓ -49.3%
Long-Term Debt Long-term obligations
$196.59M
— -0.1%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
76
Returns
93
Financial Health
83
Cash Quality
29

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 73 quarters